|
1
|
Beasley RP: Rocks along the road to the
control of HBV and HCC. Ann Epidemiol. 19:231–234. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cho EJ, Kim SE, Suk KT, An J, Jeong SW,
Chung WJ and Kim YJ: Current status and strategies for hepatitis B
control in Korea. Clin Mol Hepatol. 23:205–211. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Younossi Z, Kochems K, de Ridder M, Curran
D, Bunge EM and de Moerlooze L: Should adults with diabetes
mellitus be vaccinated against hepatitis B virus? A systematic
review of diabetes mellitus and the progression of hepatitis B
disease. Hum Vaccin Immunother. 13:2695–2706. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Szabo G and Bala S: Alcoholic liver
disease and the gut-liver axis. World J Gastroenterol.
16:1321–1329. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zhang D, Hao X, Xu L, Cui J, Xue L and
Tian Z: Intestinal flora imbalance promotes alcohol-induced liver
fibrosis by the TGFβ/smad signaling pathway in mice. Oncol Lett.
14:4511–4516. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mou H, Yang F, Zhou J and Bao C:
Correlation of liver function with intestinal flora, vitamin
deficiency and IL-17A in patients with liver cirrhosis. Exp Ther
Med. 16:4082–4088. 2018.PubMed/NCBI
|
|
7
|
Macfarlane LA and Murphy PR: MicroRNA:
Biogenesis, function and role in cancer. Curr Genomics. 11:537–561.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Fisher K and Lin J: MicroRNA in
inflammatory bowel disease: Translational research and clinical
implication. World J Gastroenterol. 21:12274–12282. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Peck BC, Weiser M, Lee SE, Gipson GR, Iyer
VB, Sartor RB, Herfarth HH, Long MD, Hansen JJ, Isaacs KL, et al:
MicroRNAs classify different disease behavior phenotypes of crohn's
disease and may have prognostic utility. Inflamm Bowel Dis.
21:2178–2187. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chiang Y, Song Y, Wang Z, Liu Z, Gao P,
Liang J, Zhu J, Xing C and Xu H: microRNA-192, −194 and −215 are
frequently downregulated in colorectal cancer. Exp Ther Med.
3:560–566. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jones MF, Hara T, Francis P, Li XL, Bilke
S, Zhu Y, Pineda M, Subramanian M, Bodmer WF and Lal A: The
CDX1-microRNA-215 axis regulates colorectal cancer stem cell
differentiation. Proc Natl Acad Sci USA. 112:E1550–E1558. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fischer J, Walker LC, Robinson BA,
Frizelle FA, Church JM and Eglinton TW: Clinical implications of
the genetics of sporadic colorectal cancer. ANZ J Surg.
89:1224–1229. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Moloney GM, Viola MF, Hoban AE, Dinan TG
and Cryan JF: Faecal microRNAs: Indicators of imbalance at the
host-microbe interface? Benef Microbes. 9:175–183. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dalmasso G, Nguyen HT, Yan Y, Laroui H,
Charania MA, Ayyadurai S, Sitaraman SV and Merlin D: Microbiota
modulate host gene expression via microRNAs. PLoS One.
6:e192932011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu S, da Cunha AP, Rezende RM, Cialic R,
Wei Z, Bry L, Comstock LE, Gandhi R and Weiner HL: The host shapes
the gut Microbiota via fecal MicroRNA. Cell Host Microbe. 19:32–43.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pan W, Zhang Y, Zeng C, Xu F, Yan J and
Weng J: miR-192 is upregulated in T1DM, regulates pancreatic β-cell
development and inhibits insulin secretion through suppressing
GLP-1 expression. Exp Ther Med. 16:2717–2724. 2018.PubMed/NCBI
|
|
17
|
Yun Y, Chang Y, Kim HN, Ryu S, Kwon MJ,
Cho YK, Kim HL, Cheong HS and Joo EJ: Alterations of the gut
microbiome in chronic hepatitis B virus infection associated with
alanine aminotransferase level. J Clin Med. 8:1732019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Lin PY, Chen SC, Lo TC and Kuo HW: Dual
infection with hepatitis B virus and hepatitis C virus correlated
with type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes.
128:38–42. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xie QH, He XX, Chang Y, Jiang X and Lin
JS: HBx gene down-regulates miR-192 expression and inhibits
apoptosis of human hepatoma cell line HepG2. Zhonghua Gan Zang Bing
Za Zhi. 19:857–860. 2011.(In Chinese). PubMed/NCBI
|
|
20
|
Yuan X, Ni H, Chen X, Feng X, Wu Q and
Chen J: Identification of therapeutic effect of glucagon-like
peptide 1 in the treatment of STZ-induced diabetes mellitus in rats
by restoring the balance of intestinal flora. J Cell Biochem.
119:10067–10074. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Shin EC, Sung PS and Park SH: Immune
responses and immunopathology in acute and chronic viral hepatitis.
Nat Rev Immunol. 16:509–523. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ou JH: Molecular biology of hepatitis B
virus e antigen. J Gastroenterol Hepatol. 12:S178–S187. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ben Q, Li Z, Liu C, Cai Q, Yuan Y, Wang K,
Xiao L, Gao J and Zhang H: Hepatitis B virus status and risk of
pancreatic ductal adenocarcinoma: A case-control study from China.
Pancreas. 41:435–440. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li YT, Wang L, Chen Y, Chen YB, Wang HY,
Wu ZW and Li LJ: Effects of gut microflora on hepatic damage after
acute liver injury in rats. J Trauma. 68:76–83. 2010.PubMed/NCBI
|
|
25
|
Neelam K, Goenadi CJ, Lun K, Yip CC and Au
Eong KG: Putative protective role of lutein and zeaxanthin in
diabetic retinopathy. Br J Ophthalmol. 101:551–558. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Boni V, Bitarte N, Cristobal I, Zarate R,
Rodriguez J, Maiello E, Garcia-Foncillas J and Bandres E:
miR-192/miR-215 influence 5-fluorouracil resistance through cell
cycle-mediated mechanisms complementary to its post-transcriptional
thymidilate synthase regulation. Mol Cancer Ther. 9:2265–2275.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hu F, Meng X, Tong Q, Liang L, Xiang R,
Zhu T and Yang S: BMP-6 inhibits cell proliferation by targeting
microRNA-192 in breast cancer. Biochim Biophys Acta.
1832:2379–2390. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Agarwal V, Bell GW, Nam JW and Bartel DP:
Predicting effective microRNA target sites in mammalian mRNAs.
Elife. 4:e050052015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hutin YJ, Bulterys M and Hirnschall GO:
How far are we from viral hepatitis elimination service coverage
targets? J Int AIDS Soc. 21 (Suppl 2):e250502018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Milich D and Liang TJ: Exploring the
biological basis of hepatitis B e antigen in hepatitis B virus
infection. Hepatology. 38:1075–1086. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Khella HW, Bakhet M, Allo G, Jewett MA,
Girgis AH, Latif A, Girgis H, Von Both I, Bjarnason GA and Yousef
GM: miR-192, miR-194 and miR-215: A convergent microRNA network
suppressing tumor progression in renal cell carcinoma.
Carcinogenesis. 34:2231–2239. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang L, Zhou W, Velculescu VE, Kern SE,
Hruban RH, Hamilton SR, Vogelstein B and Kinzler KW: Gene
expression profiles in normal and cancer cells. Science.
276:1268–1272. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rashid H, Hossain B, Siddiqua T, Kabir M,
Noor Z, Ahmed M and Haque R: Fecal microRNAs as potential
biomarkers for screening and diagnosis of intestinal diseases.
Front Mol Biosci. 7:1812020. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Sarshar M, Scribano D, Ambrosi C, Palamara
AT and Masotti A: Fecal microRNAs as innovative biomarkers of
intestinal diseases and effective players in host-microbiome
interactions. Cancers (Basel). 12:21742020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Honda K and Littman DR: The microbiome in
infectious disease and inflammation. Annu Rev Immunol. 30:759–795.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kim M and Zhang X: The profiling and role
of miRNAs in diabetes mellitus. J Diabetes Clin Res. 1:5–23.
2019.PubMed/NCBI
|
|
38
|
Holst JJ, Vilsboll T and Deacon CF: The
incretin system and its role in type 2 diabetes mellitus. Mol Cell
Endocrinol. 297:127–136. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kieffer TJ and Habener JF: The
glucagon-like peptides. Endocr Rev. 20:876–913. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Flint A, Raben A, Astrup A and Holst JJ:
Glucagon-like peptide 1 promotes satiety and suppresses energy
intake in humans. J Clin Invest. 101:515–520. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Verdich C, Flint A, Gutzwiller JP, Näslund
E, Beglinger C, Hellström PM, Long SJ, Morgan LM, Holst JJ and
Astrup A: A meta-analysis of the effect of glucagon-like peptide-1
(7–36) amide on ad libitum energy intake in humans. J Clin
Endocrinol Metab. 86:4382–4389. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dickson SL, Shirazi RH, Hansson C,
Bergquist F, Nissbrandt H and Skibicka KP: The glucagon-like
peptide 1 (GLP-1) analogue, exendin-4, decreases the rewarding
value of food: A new role for mesolimbic GLP-1 receptors. J
Neurosci. 32:4812–4820. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meeran K, O'Shea D, Edwards CM, Turton MD,
Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, et
al: Repeated intracerebroventricular administration of
glucagon-like peptide-1-(7–36) amide or exendin-(9–39) alters body
weight in the rat. Endocrinology. 140:244–250. 1999. View Article : Google Scholar : PubMed/NCBI
|
